NTRK1 and ovarian carcinoma: PDK1 has also been shown to be implicated in ovarian cancer aggressiveness via a short form of the Ron receptor tyrosine kinase [17], and COLL11A1 [18], whereas its pharmacological inhibition had been previously found to be able to enhance the effect of chemotherapeutic drugs in the ovarian cancer cell line SKOV-3 cells [19].